The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- RaQualia Begins PI Study for 5-HT4 Partial Agonist in UK
June 5, 2012
- Eisai Files for Triple Formulation Packs Including Pariet for H. Pylori Eradication
June 4, 2012
- SymBio to Postpone Filing for Supplemental NDA of Treakisym for Indication of Aggressive NHL
June 4, 2012
- Janssen Research & Development Files NDA for MTPC’s SGLT-2 Canagliflozin in the US
June 4, 2012
- Sawai Ranked Forerunner Among Drug Makers to Sell 3 Major Generics: Pharmacist Survey
June 1, 2012
- Ono Pharmaceutical to Collaborate with UK Company in Research of Drug Targets for Allergic Diseases
June 1, 2012
- Taiho to Initiate Global PIII Trial for Anticancer Agent TAS-102 in June
June 1, 2012
- MicroBiopharm Japan Announces Joint R&D Agreement with Eisai in Search of Compounds Derived from Natural Substances
June 1, 2012
- “Some Aspects Might Have Been Overlooked” in Actavis Adaptation Scenario: ASKA President Yamaguchi
May 31, 2012
- CJ CheilJedang of Korea to hold R&D Forum with 6 Ventures in Japan
May 31, 2012
- Kyowa Kirin Launches Its First Antibody Drug Poteligeo for ATL
May 31, 2012
- Pfizer Launches ALK Inhibitor Xalkori, Administered to 51 Patients Prior to NHI Price Listing
May 30, 2012
- Kyorin Holdings to Boost Manufacturing System with Transfer of MSD Plant
May 30, 2012
- Shionogi Launches Oxycodone Injections in Response to Request for Development
May 30, 2012
- Takeda Launches ARB Azilva; Will Target Patients Inadequately Controlled with Existing Medications
May 30, 2012
- Cardiovascular Agent Market Increases 2.6% to 1.363 Billion Yen in 2011: Fuji-Keizai
May 30, 2012
- Takeda to Acquire Multilab of Brazil to Boost Business Infrastructure through OTC Drugs
May 29, 2012
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…